论文部分内容阅读
目的:对比分析糖尿病患者采取国产与进口阿卡波糖联合格列吡嗪治疗的临床疗效及成本,以便寻求经济与有效的治疗方法。方法:将80例2型糖尿病患者随机均分为国产组与进口组,各自40例。其中国产组患者采取国产阿卡波糖联合格列吡嗪治疗,而进口组患者采取进口阿卡波糖联合格列吡嗪治疗,观察记录两组患者临床治疗效果、成本、不良反应,并进行对比分析。结果:国产组治疗总有效率为90.00%(36/40),进口组则为92.50%(37/40),两组总有效率对比无显著性差异(P>0.05);国产组降糖药月均费用209.25±16.85元,进口组则为288.45±15.46元,国产组降糖药月均费用明显比进口组低,对比差异有统计学意义(P<0.01);国产组发生不良反应2例,进口组发生3例,两组不良反应发生率无显著性差异(P>0.05)。结论:糖尿病患者采取国产与进口阿卡波糖联合格列吡嗪治疗,两者在不良反应发生率、治疗效果上并无显著性差异,疗效皆确切且安全性高,但国产阿卡波糖联合格列吡嗪治疗成本更低,属于经济有效的方式,值得借鉴。
Objective: To compare and analyze the clinical efficacy and cost of taking domestic and imported acarbose plus glipizide in patients with diabetes in order to seek economical and effective treatment. Methods: 80 patients with type 2 diabetes were randomly divided into domestic group and imported group, 40 cases in each. The patients in the Chinese group were treated with domestic acarbose and glipizide, while those in the imported group were treated with acarbose and glipizide. The clinical effects, costs and adverse reactions of the two groups were observed and recorded Comparative analysis. Results: The total effective rate was 90.00% (36/40) in domestic group and 92.50% (37/40) in imported group, there was no significant difference between the two groups in total effective rate (P> 0.05) The monthly average cost was 209.25 ± 16.85 yuan, while the import group was 288.45 ± 15.46 yuan. The average monthly cost of hypoglycemic drugs in domestic group was significantly lower than that in imported group (P <0.01). There were 2 adverse reactions in domestic group There were 3 cases in the imported group, with no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion: Diabetic patients treated with acarbose and imported glipizide, both in the incidence of adverse reactions, the treatment effect was no significant difference in the efficacy of both accurate and safe, but the domestic acarbose The combination of glipizide treatment costs lower, is a cost-effective way, it is worth learning.